Two systematic reviews and meta-analyses on endometrial cancer risk in BRCA1 and BRCA2 carriers show a slight increased relative risk of serous endometrial cancer in BRCA1 (Standardised Incidence Ratio 2.81) and BRCA2 (Standardised Incidence Ratio 1.75)20,21 but minimal increase in absolute risk. This evidence concerns the gene BRCA2 and endometrial cancer.